UroGen Pharma Ltd.

URGNNASDAQBeobachtung

US$46.18

-0.4 % today

COMPANY DATA

Sector: HealthcareIndustry: BiotechnologyCountry: USCEO: Elizabeth BarrettEmployees: 300Market cap: 2.2 BIPO: 04/05/2017Web: www.urogen.com

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant…

PRICE HISTORY

26/08/25+135.7 %26/08/26

1D

-0.9 %

1W

-8.6 %

1M

+10.9 %

6M

+122.4 %

YTD

+96.2 %

1Y

+135.7 %

2Y

+221.6 %

5Y

+170.5 %

10Y

–

EARNINGS

Next earnings date

05/11/2026 (in 71 days)

Volatility around earnings

~19% stronger price swings than usual

SCORES

Valuation

Valued significantly cheaper than its own historical average.

Why this value? Details with Pro only.

Trend

Clear uptrend.

Why this value? Details with Pro only.

Quality

Weak balance sheet quality or high debt.

Why this value? Details with Pro only.

Dividend

Not enough data yet for an assessment.

Growth

Strong expected growth at a fair price.

Why this value? Details with Pro only.

Insider

Insiders are selling more shares than they buy.

Why this value? Details with Pro only.

Earnings

Roughly meets expectations.

Why this value? Details with Pro only.

Revisions

Significantly more upgrades than downgrades from analysts recently.

Why this value? Details with Pro only.

Sentiment

Not enough data yet for an assessment.

Short Pressure

Elevated short volume ratio.

Why this value? Details with Pro only.

Register for free

Unlock all 9 scores

4 credits free on registration
Access to virtual portfolios and watchlist
No credit card, no payment details needed
No subscription, no minimum term
Our own servers in Germany, no US cloud

Create account →

Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 26/08/2026.

ASK THE AGENTS ABOUT URGN

ANALYST ASSESSMENT

PRICE TARGET LOW

US$40.00

CONSENSUS

US$53.40

MEDIAN

US$50.00

PRICE TARGET HIGH

US$75.00

0

STRONG BUY

12

BUY

4

HOLD

0

SELL

0

STRONG SELL

16

TOTAL · Buy

DATE	ANALYST FIRM	RATING	ACTION
06/08/2026	HC Wainwright & Co.	Buy	maintain
06/08/2026	Guggenheim	Buy	maintain
05/08/2026	TD Cowen	Buy	maintain
21/07/2026	Guggenheim	Buy	maintain
16/07/2026	Oppenheimer	Outperform	maintain
03/06/2026	HC Wainwright & Co.	Buy	maintain
18/05/2026	HC Wainwright & Co.	Buy	maintain
11/05/2026	HC Wainwright & Co.	Buy	maintain

METRICS

P/E

-23.32

P/B

-17.57

EV/EBITDA

-33.47

RETURN ON EQUITY

10.8 %

NET MARGIN

-19.8 %

DEBT/EQUITY

-1.48

DIVIDEND YIELD

0 %

AS OF

30/06/2026

FREE FLOAT & LIQUIDITY

FREE FLOAT

88.9 %

FLOAT SHARES

43,336,042

AVG. DAILY VOLUME (30D)

904,358

INSIDER TRANSACTIONS (SEC)

DATE	INSIDER	ROLE	TRANSACTION	SHARES	PRICE	PLAN TYPE
24/08/2026	Schoenberg Mark	Officer	Sale	60,677	47.05	Spontaneous
10/07/2026	Schoenberg Mark	Officer	Sale	10,000	40	Pre-planned
24/06/2026	Schoenberg Mark	Officer	Sale	10,000	35.01	Pre-planned
09/06/2026	Schoenberg Mark	Officer	Sale	5,222	27.3	Spontaneous
09/06/2026	Schoenberg Mark	Officer	Option exercise	10,000	–	Spontaneous

Page 1 / 2

INSTITUTIONAL HOLDERS

FUND / INSTITUTION	SHARES	CHANGE	AS OF
HRT FINANCIAL LP	0	-49,363	30/06/2026
Vestal Point Capital, LP	0	-139,079	30/06/2026
TORONTO DOMINION BANK	0	-2,616,714	30/06/2026
TCG Crossover Management, LLC	0	-405,365	30/06/2026
TANG CAPITAL MANAGEMENT LLC	0	-350,000	30/06/2026

Page 1 / 3

Not investment advice. Past performance is not an indicator of future results.